An International Prospective Observational Study to Assess the Characteristics and Outcomes of Post-transplant Patients Treated for C. Difficile Infections
CDIFF - An International Prospective Observational Study to Assess the Characteristics and Outcomes of Post-transplant Patients Treated for C. Difficile Infections
What is this study about?
Clostridium difficile is bacteria that can cause infection of the colon, and produce a substance that causes belly pain and diarrhoea.
This study is being done to better understand CDIFF infections after a transplant. It will look at the outcome of treatment for CDIFF infections. We are interested in how long infections last, if they occur more than once, what treatments are given and how well they work.
Type of study
Who is funding the study?
Merck & Co., Inc and Astellas Pharma.
When is it taking place?
CDIFF opened in August 2016. We expect the study will conclude by the end of October 2018.
Where is it taking place?
CDIFF is taking place in France, Denmark, Spain, Sweden, Germany, Argentina and the USA.
Who is included?
To join CDIFF participants have CDIFF infection and have had a transplant in the last 2 years.